MapLight Therapeutics (MPLT) Assets Average (2025)
MapLight Therapeutics recorded quarterly Assets Average of $368.4 million in Q4 2025, up 86.92% quarter-over-quarter from $197.1 million in Q3 2025.
MapLight Therapeutics' Assets Average history runs 1 years deep, the most recent figure standing at $368.4 million for Q4 2025.
- In Q4 2025, Assets Average changed N/A year-over-year to $368.4 million; the TTM figure through Dec 2025 stood at $368.4 million (changed N/A YoY), while the FY2025 annual figure was $308.2 million, changed N/A from the prior year.
- Assets Average came in at $368.4 million for Q4 2025 at MapLight Therapeutics, up from $197.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $368.4 million in Q4 2025 to a low of $197.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 368.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 368.37 Mn |
| Sep 30, 2025 | 197.07 Mn |